Helicobacter-pylori Infektion - ein Update 2004

Auch im Jahr 2004 bleibt die Beschäftigung mit der Helicobacter-pylori(H.p.)-Infektion eine spannende Herausforderung für Klinik und Grundlagenforschung [46]. Die H.p.-Therapie zur Heilung der peptischen Ulkuskrankheit ist zwar allgemein akzeptiert, allerdings lässt die letzte Konsequenz der Umsetzung dieser Behandlung in der Praxis immer noch Wünsche offen. Die klinische Diskussion dreht sich weiterhin um Indikationsstellungen zur Behandlung der H.p.-Infektion, wenn noch keine Komplikationen eingetreten sind. Aktuell sind vor allem Fragen, ob Patienten mit dyspeptischen Beschwerden bei H.p.-positiver Gastritis von dieser Therapie profitieren, ob die Behandlung der Infektion vor Schäden durch nicht-steroidale Antirheumatika (NSAR) schützt, und nicht zuletzt, ob eine Prävention des Magenkarzinoms durch H.p.-Eradikation erreicht werden kann.

Literatur

• 1 Birkner B, Hotz J, Labenz J. et al . Kurzgefasste Leitlinie zum Dyspepsie-Management.  Dtsch Med Wochenschr. 2004;  129 (18) 1032-1034
• 2 Blaser M J. Hypothesis: the changing relationship of H.p. and humans: implications for health and disease.  J Infect Dis. 1999;  179 1523-1530
• 3 Brenner H, Arndt V, Stegmaier C. et al . Is H.p. infection a necessary condition for noncardia gastric cancer?.  Am J Epidemiol. 2004;  159 252-258
• 4 Chan F K, Chung S C, Suen B Y. et al . Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen.  N Engl J Med. 2001;  344 967-973
• 5 Chan F K, To K F, Wu J C. et al . Eradication of H.p. and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial.  Lancet. 2002;  359 9-13
• 6 Chiba N, Veldhuyzen Van Zanten S JO, Escobedo S. et al . Economic evaluation of H.p. eradication in the CADET-Hp randomized controlled trial of H.p. positive primary care patients with uninvestigated dyspepsia.  Aliment Pharmacol Ther. 2004;  19 349-358
• 7 Chiba N, Veldhuyzen Van Zanten S JO, Sinclair P. et al . Treating H.p. infection in primary care patients with uninvestigated dyspepsis: the Canadian adult dyspepsia empiric treatment - H.p. positive (CADET-Hp) randomised controlled trial.  Brit Med J. 2002;  324 1-7
• 8 Churin Y, Al-Ghoul L, Kepp O. et al . Helicobacter pylori CagA protein targets the c-Met receptor and enhances the motogenic response.  J Cell Biol. 2003;  28 (161) 249-255
• 9 Dore M P, Osato M S, Malaty H M. et al . Characterization of a culture method to recover Helicobacter pylori from the feces of infected patients.  Helicobacter. 2000;  5 165-168
• 10 El Omar E M, Rabkin C S, Gammon M D. et al . Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms.  Gastroenterology. 2003;  124 1193-201
• 11 Fischbach W, Goebeler-Kolve M E, Dragosics B. et al . Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series.  Gut. 2004;  53 34-37
• 12 Gisbert J, Calvet X, Bujanda L. et al . ’Rescue’ therapy with rifabutin after multiple Helicobacter pylori treatment failures.  Helicobacter. 2003;  8 90-94
• 13 Glupczynski Y, Megraud F, Lopez-Brea M. et al . European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori.  Eur J Clin Microbiol Infect Dis. 2001;  20 820-823
• 14 Glynn M K, Friedman C R, Gold B D. et al . Seroincidence of Helicobacter pylori infection in a cohort of rural Bolivian children: acquisition and analysis of possible risk factors.  Clin Infect Dis. 2002;  35 1059-1065
• 15 Granquist A, Bredberg A, Sveger T. et al . A longitudinal cohort study on the prevalence of Helicobacter pylori antibodies in Swedish children and adolescents.  Acta Paediatr. 2002;  91 636-640
• 16 Grimm W, Fischbach W. Helicobacter pylori infection in children and juveniles: an epidemiological study on prevalence, socio-economic factors and symptoms.  Dtsch Med Wochenschr. 2003;  128 1878-1883
• 17 Heuberger F, Pantoflickowa D, Gassner M. et al . H.p. infection in Swiss adolescents. Prevalence and risk factors.  Eur J Gastroenterol Hepatol. 2003;  15 179-183
• 18 Huang J, Hunt R. The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxicillin or metronidazole.  Aliment Pharmacol Ther. 1999;  13 857-64
• 19 Kist M, Glocker E. Helicobacter pylori Infektionen: ResiNet - eine bundesweite Sentinelstudie zur Resistenzentwicklung.  Epidemiol Bull. 2003;  47 389-391
• 20 Klotz U, Schwab M, Treiber G. CYP2C19 Polymorphism and Proton Pump Inhibitors.  Basic Clin Pharmacol Toxicol. 2004;  95 2-8
• 21 Kuipers E J, Nelis G F, Klinkenberg-Knol E C. et al . Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial.  Gut. 2004;  53 12-20
• 22 Labenz J, Blum A L, Bolten W W. et al . Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in H.p. positive patients: a randomised, double blind, placebo controlled, clinical trial.  Gut. 2002;  51 329-335
• 23 Lai K C, Lam S K, Chu K M. et al . Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use.  N Engl J Med. 2002;  346 2033-2038
• 24 Leodolter A, Dominguez-Munoz J E, Von Arnim U. et al . Validity of a modified 13C-urea breath test for pre- and posttreatment diagnosis of Helicobacter pylori infection in the routine clinical setting.  Am J Gastroenterol. 1999;  94 2100-2104
• 25 Leodolter A, Malfertheiner P. Aktuelle diagnostische Methoden zum Nachweis der Helicobacter-pylori-Infektion.  Dtsch Med Wochenschr. 2001;  126 207-209
• 26 Leodolter A, Wolle K, Malfertheiner P. Current standards in the diagnosis of H. pylori infection.  Dig Dis. 2001;  19 116-122
• 27 Leodolter A, Peitz U, Ebert M P. et al . Comparison of two enzyme immunoassays for the assessment of Helicobacter pylori status in stool specimens after eradication therapy.  Am J Gastroenterol. 2002;  97 1682-1686
• 28 Leodolter A, Vaira D, Bazzoli F. et al . European multicentre validation trial of two new non-invasive tests for the detection of Helicobacter pylori antibodies: urine-based ELISA and rapid urine test.  Aliment Pharmacol Ther. 2003;  18 927-931
• 29 Leodolter A, Wolle K, Peitz U. et al . Evaluation of a near-patient fecal antigen test for the assessment of Helicobacter pylori status.  Diagn Microbiol Infect Dis. 2004;  48 145-147
• 30 Malfertheiner P. H.p. eradication does not exacerbate gastro-oesophageal reflux disease.  Gut. 2004;  53 312-313
• 31 Malfertheiner P, Megraud F, O’Morain C. et al . Current concepts in the management of Helicobacter pylori infection - The Maastricht 2 - 2000 Consensus Report.  Aliment Pharmacol Ther. 2002;  16 167-180
• 32 Malfertheiner P, Mössner J, Fischbach W. et al . H.p. eradication is beneficial in the treatment of functional dyspepsia.  Aliment Pharmacol Ther. 2003;  15 615-625
• 33 Malfertheiner P, Peitz U, Treiber G. What constitutes failure for Helicobacter pylori eradication therapy?.  Can J Gastroenterol. 2003;  17 (Suppl B) 53B-57B
• 34 Manes G, Menchise A, De Nucci C. et al . Empirical prescribing for dyspepsia. randomised controlled trial of test and treat versus omeprazole treatment.  Brit Med J. 2003;  326 1118
• 35 Mc Coll K EL, Murray L S, Gillen D. et al . Randomised trial of endoscopy with testing for Helicobacter pylori compared with non-invasive H.p. testing alone in the management for dyspepsia.  Brit Med J. 2002;  324 999-1002
• 36 Meining A G, Bayerdorffer E, Stolte M. Helicobacter pylori gastritis of the gastric cancer phenotype in relatives of gastric carcinoma patients.  Eur J Gastroenterol Hepatol. 1999;  11 717-720
• 37 Melo E T, Lopes E P, Almeida J R, Albuquerque  H F, Moura I M. Seroprevalence of H. pylori antibodies in medical students and residents in Recife, Brazil.  Clin Gastroenterol. 2003;  36 134-8
• 38 Mitchell H M, Hu P, Chi Y. et al . A low rate of reinfection following effective therapy against Helicobacter pylori in a developing nation.  Gastroenterology. 1998;  114 256-261
• 39 Nardone G, Morgner A. Helicobacter pylori and gastric malignancies.  Helicobacter. 2003;  8,1 44-52
• 40 Osato M S, Reddy R, Graham D Y. Metronidazole and clarithromycin resistance amongst Helicobacter pylori isolates from a large metropolitan hospital in the United States.  Int J Antimicrob Agents. 1999;  12 341-347
• 41 Peitz U, Leodolter A, Wex T. et al . Diagnostics of Helicobacter pylori infection in patients with peptic ulcer bleeding.  Z Gastroenterol. 2004;  42 141-146
• 42 Raymond J, Kalach N, Bergeret M. et al . Prevalence of Helicobacter pylori infection in children according to their age. A retrospective study.  Arch Pediatr. 1998;  5 617-620
• 43 Roma-Giannikou E, Karameris A, Balatsos B. et al . Intrafamilial spread of Helicobacter pylori: a genetic analysis.  Helicobacter. 2003;  8 15-20
• 44 Rothenbacher D, Brenner H. Burden of H.p. and H.p.-related diseases in developed countries: recent developments and future implications.  Microbes Infect. 2003;  5 (8) 693-703
• 45 Schilling D, Demel A, Adamek H E. et al . A negative rapid urease test is unreliable for exclusion of Helicobacter pylori infection during acute phase of ulcer bleeding. A prospective case control study.  Dig Liver Dis. 2003;  35 217-221
• 46 Suerbaum S, Michetti P. Helicobacter pylori infection.  N Engl J Med. 2002;  347 1175-86
• 47 Triantafillidis J K, Gikas A, Hyphantis T. et al . Helicobacter pylori infection in hospital workers over a 5-year period. Correlation with demographic and clinical parameters.  J Gastroenterol. 2002;  37 1005-1013
• 48 Uemura N, Okamoto S, Yamamoto S. et al . H.p. infection and the development of gastric cancer.  N Engl J Med. 2001;  345 784-789
• 49 Wolle K, Leodolter A, Malfertheiner P. et al . Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000.  J Med Microbiol. 2002;  51 705-9
• 50 Wong B CY, Lam S K, Wong W M. et al . H.p. eradication to prevent gastric cancer in a high-risk region of China.  J Amer Med Assoc. 2004;  291 (2) 187-194